A Meta-Analysis of the Therapeutic Effects of Glucagon-Like Peptide-1 Agonist in Heart Failure

Table 1

Summary of all trials studying GLP-1 effects in human heart failure.

Study	Endpoints
Thrainsdottir et al., 2004 [30]	HR, BP (rest + exercise), rate pressure product, global systolic and diastolic function, LVEF, LV end-diastolic diameter
Nikolaidis et al., 2004 [20]	LVEF, ED +ESV, SV, global WMSI
Sokos et al., 2006 [31]	HR, BNP, LVEF, VO2, 6-min walk
Halbirk et al., 2010 [32]	BNP, BP, HR, SV, CI, LVEF, SVR, 6 min hall walk test